Klinikum St Marien Amberg
- Address
- lock Available on a paid plan
Digestive System Diseases
The department is actively evaluating new treatment strategies for colorectal cancer, including molecularly targeted approaches for KRAS‑mutated tumors and adjuvant therapies guided by circulating tumor DNA.
- colorectal cancer research
- gastric and esophagogastric junction studies
- rectal cancer organ preservation trials
At Klinik für Frauenheilkunde und Geburtshilfe of Klinikum St Marien Amberg, investigators are testing combinatorial regimens to improve disease‑free survival after surgery.
Neoplasms
Clinical programs focus on hormone‑responsive and HER2‑negative breast cancers as well as high‑grade ovarian and endometrial malignancies, aiming to enhance survival with novel endocrine and antibody‑based combinations.
- early‑stage hormone receptor‑positive breast cancer
- advanced ovarian and fallopian tube cancer
- B7‑H4‑selected endometrial carcinoma trials
The site’s multidisciplinary team integrates surgical, medical and radiation expertise to assess therapeutic benefit and quality‑of‑life outcomes.
Respiratory Tract Diseases
Research concentrates on non‑small cell lung cancer, particularly KRAS‑mutated and PD‑L1‑high subtypes, evaluating immunotherapy‑based regimens to extend progression‑free survival.
- KRAS G12C mutant lung cancer
- TTF‑1 negative adenocarcinoma studies
- immunotherapy plus chemotherapy combinations
Collaboration with pulmonology specialists enables comprehensive patient monitoring throughout trial participation.
Hemic and Lymphatic Diseases
Trials address aggressive B‑cell lymphomas and chronic lymphocytic leukaemia, testing targeted agents such as BTK inhibitors, venetoclax and novel monoclonal antibodies to improve response rates.
- diffuse large B‑cell lymphoma (DLBCL) investigations
- high‑risk chronic lymphocytic leukaemia studies
- follicular lymphoma progression‑free survival trials
The hematology unit leverages advanced imaging and molecular profiling to tailor therapy for each patient cohort.
Congenital, Hereditary, and Neonatal Diseases
A dedicated neonatal program evaluates closed‑loop oxygen control systems for extremely preterm infants, seeking to reduce complications such as retinopathy of prematurity and bronchopulmonary dysplasia.
- preterm infant respiratory support research
- automated FiO₂ regulation studies
- neonatal outcome and neurodevelopment follow‑up
By integrating neonatal intensive care expertise, the site aims to set new standards for safe oxygen delivery in the most vulnerable patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 68 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 67 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum St Marien Amberg
lock Showing 1 of 34 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 68 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 9 | Unknown | 2018-09-03 | 2025-12-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.